Status: Recruiting
Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.
Participants needed: 125
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Bo LuUpdated: Jul 30, 2026Locations: 3
Eligibility criteria
Patient older than 18 years age [+6]
Prior thoracic radiotherapy to chest. [+2]